Rigel Pharmaceuticals

The FDA granted fast track designation to R289, a dual IRAK1 and IRAK4 inhibitor, for treating transfusion-dependent lower-risk myelodysplastic syndrome. Rigel Pharmaceuticals is investigating R289 in a phase 1b study, aiming to address limited treatment options for elderly patients with progressive cytopenias, particularly anemia.

DelveInsight's report on Thrombocytopenia Market (2034) covers epidemiology, market trends in the US, EU4, UK, and Japan, highlighting the US as the largest market. Key companies include Sanofi, Principia Biopharma, Baxalta, Takeda, and others. Promising therapies such as VLX-1005, Herombopag, Avatrombopag Oral Tablet, Rilzabrutinib, and Nipocalimab are noted. Clinical trials by Qidong Gaitianli Medicines, Karyopharm Therapeutics, Janssen Research & Development, and Amgen are scheduled for June 2024. Marketed drugs like ADZYNMA (Takeda) and TAVALISSE (Rigel Pharmaceuticals/Kissei Pharmaceutical) are discussed. Emerging drugs like Rilzabrutinib (Sanofi/Principia Biopharma) are in Phase III for ITP treatment.

The 'T-Cell Lymphoma Pipeline Insight Analysis Report' highlights key players like Legend Biotech, Eisai, Takeda, and Rhizen Pharmaceuticals developing treatments such as Lenalidomide, BMS-986369, and Isatuximab SAR650984. Regulatory support, including fast-track designations, drives innovation, aiming for better patient outcomes. The pipeline focuses on immune-modulating drugs, monoclonal antibodies, and targeted therapies, with Phase II trials dominating.

The T-Cell Lymphoma Pipeline Insight Analysis Report highlights key players like Legend Biotech, Eisai, Takeda, and Rhizen Pharmaceuticals developing therapies such as Lenalidomide, BMS-986369, and Isatuximab SAR650984. Regulatory support, including fast-track designations, accelerates novel treatment development, aiming to improve patient outcomes in this aggressive cancer.

Rigel Pharmaceuticals warns clinicians of severe and fatal infections in lung cancer patients treated with pralsetinib, based on an ad-hoc analysis of the AcceleRET-Lung trial. The analysis showed a higher risk of severe infections in the pralsetinib group compared to standard of care, including fatal infections and opportunistic infections. Healthcare providers are advised to monitor patients closely and manage infections according to guidelines.

The K2 trial of oditrasertib, designed to reduce neuronal damage biomarker in MS, failed to meet primary and secondary endpoints. Denali and Sanofi's partnership faced setbacks with other RIPK1 inhibitors, including a phase 2 ALS trial failure. Despite challenges, the MS treatment market is projected to grow significantly.

Rigel Pharmaceuticals, Inc. announced that CEO Raul Rodriguez will present at the Cantor Global Healthcare Conference on September 19 at 9:10 am ET in New York. The presentation will be available via live webcast on Rigel's website.

Rigel Pharmaceuticals enrolls first subject in Phase Ib/II trial of REZLIDHIA (olutasidenib) combined with decitabine and venetoclax for mIDH1 AML, aiming to determine safety and complete remission rate. This trial marks the first under a multi-year strategic alliance with MD Anderson, exploring olutasidenib's potential in various hematologic neoplasms.

Rigel Pharmaceuticals announced the first patient enrolled in a Phase 1b/2 triplet therapy trial of REZLIDHIA (olutasidenib) combined with decitabine and venetoclax for mIDH1 AML, conducted by MD Anderson. The trial aims to determine safety, tolerability, and complete remission rates in newly diagnosed and relapsed/refractory patients.